Expert Opinion on Investigational Drugs

Article	Citations
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL	103
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	80
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	52
Theranostic strategies in sarcoma: preliminary clinical evidence	46
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men	42
Investigational agents targeting alarmins for asthma treatment: insights and progress from phase I and II trials	41
Current status and perspective of immunotherapy for head and neck squamous cell carcinoma	39
Endoglin-targeted cancer therapies: current status and opportunities	37
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD	36
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	32
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	29
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	29
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	28
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	26
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	25
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	25
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	25
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development	24
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	23
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development	23
Investigational drugs for the treatment of dysmenorrhea	23
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	23
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	23
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	23
Potassium channel modulators and schizophrenia: an overview of investigational drugs	22

Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?	21
Mass balance and absolute bioavailability of avenciguat ( 14 C) after intravenous or oral administration in healthy male participants	21
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su	21
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease	20
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors	20
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials	19
Endothelin receptor antagonists for diabetic kidney disease: back to the future?	19
Duchenne muscular dystrophy: promising early-stage clinical trials to watch	18
IgA nephropathy: an overview of drug treatments in clinical trials	18
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia	18
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development	18
Recent developments in adjunct therapies for type 1 diabetes	17
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration	17
Investigational new drugs for the treatment of leishmaniasis	17
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study	17
Preclinical therapeutics for sickle cell disease: modern developments and future considerations	17
What is the progress of experimental drug development for fibromyalgia?	17
Current experimental and early investigational agents for cardiac fibrosis: where are we at?	15
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials	15
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options	15
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal	15
SOT201: cis -acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors	14
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects	14
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer	14
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists	14
Assessing the clinical progress of the bispecific nanobody sonelokimab	14
NF1 alterations in cancers: therapeutic implications in precision medicine	14
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations	14
Frontotemporal dementia: from genetics to therapeutic approaches	14
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)	13
Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions	13
Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia?	13
Investigational drugs for the treatment of olfactory dysfunction	13
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease	13
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	13
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa	13
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici	13
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents	13
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	13
KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress	13
JAK inhibitors for rheumatoid arthritis	12
Navafenterol for chronic obstructive pulmonary disease therapy	12
Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years?	12
Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?	12
Investigational thrombolytic drugs for acute ischemic stroke	12
Clinical development of tri-specific antibodies for immune-oncology	11
Investigational agents for ischaemic cardiomyopathy treatment: preclinical and early phase insights	11
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents	11
Pharmacological agents for bone fracture healing: talking points from recent clinical trials	11
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis	11

Immunotherapeutic strategies for treating opioid use disorder and overdose	11
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus	11
An update on novel investigational agents for the treatment of primary biliary cholangitis	11
Investigational new drugs for the treatment of Dravet syndrome: an update	11
Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials	11
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia	11
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies	11
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer	11
Alpha-1 antitrypsin: therapeutic applications beyond serine protease inhibition	11
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study	10
Assessing potential of psilocybin for depressive disorders	10
IRAK signaling in cancers: mechanisms, targeting, and clinical implications	10
Investigational insights into the potential of angiotensin type II receptor agonists as therapeutics for idiopathic pulmonary fibrosis	10
Inflammation and Huntington’s disease – a neglected therapeutic target?	10
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma	10
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep	10
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress	10
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials	9
The impact of current investigational drugs for acne on future treatment strategies	9
Investigational anti IL-13 asthma treatments: a 2023 update	9
Mantle cell lymphoma: what clinical progress in the last 5 years?	9
The latest investigational drugs for patients with allergic rhinitis	9
Prospects of current AXL-targeting therapies in early phase cancer trials	9
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections	9
A VEGF gene therapy approach for the treatment of patients with coronary artery disease and refractory angina: assessment of clinical development	9
Menin inhibitors for adult acute myeloid leukemia: 2025 update	9
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension	9
Tafoxiparin effects on cervical ripening and labor augmentation	9
Novel agents to treat adrenal insufficiency: findings of preclinical and early clinical trials	9
Investigational drugs in early phase trials for myelofibrosis	8
Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?	8
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-c	8
Preclinical prospects of investigational agents for hearing loss treatment	8
Will new investigational drugs change the way we treat Charcot-Marie-Tooth disease?	8
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects	8
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH	8
Retinal stroke: research models, targets and experimental drugs	8
Islatravir: evaluation of clinical development for HIV and HBV	8
Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma	8
Novel investigational drugs for alopecia areata and future perspectives	8
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets	8
Topical hypericin: a promising photodynamic therapy for early-stage cutaneous T-cell lymphoma	8
Investigational drugs in early clinical development for portal hypertension	8
Investigational DNA topoisomerase I inhibitors for colorectal cancer: preclinical and early phase developments	7
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs	7
Investigational drugs for the treatment of acromegaly: new agents to transform therapy	7
Fibroblast growth factor therapies in biliary tract cancers: current and future state	7
Triple negative breast cancer: what clinical progress have we seen in the last 5 years?	7
Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials	7
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review	7
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate	7
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease	7
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape	7
AXS-05: an investigational treatment for Alzheimer’s disease-associated agitation	7
Psoriasis: talking points from recent clinical trials	7
Targeting inflammation in endometriosis: emerging therapeutic options	7
Targeting aldosterone in sleep apnea: opening a new therapeutic era	7
Insights into the anti-inflammatory and anti-arthritic potential of 3-Acetyl-11-keto-β-Boswellic Acid as a therapeutic approach in Rheumatoid Arthritis	7
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis	7
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study	7
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action	6
Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics	6
T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development	6
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study	6
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension	6
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity	6
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled do	6
Investigational drugs inhibiting complement for the treatment of geographic atrophy	6
First-in-human phase I studies of YJ001 spray applied to local skin in healthy subjects and patients with diabetic neuropathic pain	6
Clinical development of BPS804 for osteogenesis imperfecta: from failure to fruition?	6
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study	6
Retatrutide: a triple incretin receptor agonist for obesity management	6
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer	6
Bomedemstat as an investigative treatment for myeloproliferative neoplasms	6
Experimental drugs for the prevention or treatment of sensorineural hearing loss	6
Developments and challenges for new and emergent preparations for male hypogonadism treatment	6
Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development	6
Zanzalintinib (XL092): a next-generation tyrosine kinase inhibitor—comprehensive review of early safety & efficacy data	6
Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma	6
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?	6

Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials	6
Psoriasis: a focus on upcoming oral formulations	6
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies	6
Investigational new drugs to treat brain metastasis from non-small cell lung cancer	6
Correction	6
Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation	6
Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics	6
Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: res	6
Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments	5
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease	5
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma	5
A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion prote	5
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation	5
A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug	5
Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis	5
Development of investigational radiotherapeutics for the diagnosis and treatment of glioma	5
Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments	5
New insights into the management of Behçet syndrome	5
Emerging therapies for overactive bladder: preclinical, phase I and phase II studies	5
Innovative therapies under clinical development for ALS treatment: small molecules	5
Experimental and new investigational drugs for the treatment of uterine fibroids	5
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline	5
Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation	5
A focused report on IFN-1 targeted therapies for lupus erythematosus	5
Long COVID [post-acute sequelae of coronavirus disease 2019]: experimental drugs for cardiopulmonary complications	5
A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome	5
Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review	4
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects	4
Metabolic dysfunction and insulin sensitizers in acute and chronic disease	4
Avasopasem for the treatment of radiotherapy-induced severe oral mucositis	4
Venetoclax in acute myeloid leukemia	4
Insulin sensitizers in 2023: lessons learned and new avenues for investigation	4
Early stage clinical trials for the treatment of hemophilia A	4
Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease	4
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?	4
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature	4
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies	4
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidat	4
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development	4
Istaroxime – update of data in early cardiogenic shock and decompensated heart failure	4
Factor IX stimulants in preclinical and early phase trials for hemophilia B treatment	4
Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection	4
The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke	4
Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy	4
Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia	4
Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer	4
Investigational follicle-stimulating hormone receptor agonists for male infertility therapy	4
Prospects for multi-focal motor neuropathy treatment by complement inhibition	4
Polyvalent immunoglobulin therapy: preclinical evidence and potential for treating chemotherapy-induced peripheral neuropathy	4
Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases	4
Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy	4
KIF18A inhibition and its rising role in cancer therapy trials: from bench to bedside	4
Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure	4
Investigational drugs for HIV: trends, opportunities and key players	4
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions	4